Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer

被引:27
|
作者
Monge, A
Jagla, M
Lapouge, G
Sasorith, S
Cruchant, M
Wurtz, JM
Jacqmin, D
Bergerat, JP
Céraline, J
机构
[1] Univ Strasbourg 1, Lab Cancerol Expt & Radiobiol, EA 3430, IRCAD, F-67091 Strasbourg, France
[2] IGBMC, Dept Biol & Genom Struct, Illkirch Graffenstaden, France
[3] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France
[4] Hop Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France
关键词
androgen receptor; hormone-refractory prostate cancer; mutation; DNA binding specificity; transcriptional activity;
D O I
10.1007/s00018-005-5471-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-spe-cific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 50 条
  • [21] Grp78 activity is associated with Androgen Receptor status and upregulated in Hormone-Refractory prostate cancer
    Tan, S.
    Ahmad, I.
    Singh, L.
    Nixon, C.
    Edwards, J.
    Leung, H.
    EJC SUPPLEMENTS, 2010, 8 (05): : 44 - 44
  • [22] Chemotherapy of the hormone-refractory prostate cancer
    Heine, K
    Wolff, JM
    AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
  • [23] Management of hormone-refractory prostate cancer
    Dogliotti, L
    Mosca, A
    TUMORI, 2003, : S147 - S149
  • [24] Taxanes in hormone-refractory prostate cancer
    Kang, MH
    Figg, WD
    Dahut, W
    CANCER PRACTICE, 1999, 7 (05) : 270 - 272
  • [25] Therapy of hormone-refractory prostate cancer
    Heidenreich, A
    UROLOGE, 2005, 44 (12): : 1481 - 1494
  • [26] Satraplatin for hormone-refractory prostate cancer
    Kerr, Cathel
    LANCET ONCOLOGY, 2007, 8 (04): : 290 - 290
  • [27] Chemotherapy for hormone-refractory prostate cancer
    Shelley, Mike
    Harrison, Craig
    Coles, Bernadette
    Staffurth, John
    Wilt, Timothy J.
    Mason, Malcolm D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [28] Chemotherapy in hormone-refractory prostate cancer
    de Wit, Ronald
    BJU INTERNATIONAL, 2008, 101 : 11 - 15
  • [29] Therapy of hormone-refractory prostate cancer
    不详
    ANTICANCER RESEARCH, 2005, 25 (6D) : 4796 - 4796
  • [30] Update on hormone-refractory prostate cancer
    Kasamon, KM
    Dawson, NA
    CURRENT OPINION IN UROLOGY, 2004, 14 (03) : 185 - 193